U.S. markets closed
  • S&P 500

    4,551.68
    -23.11 (-0.51%)
     
  • Dow 30

    35,490.69
    -266.19 (-0.74%)
     
  • Nasdaq

    15,235.84
    +0.12 (+0.00%)
     
  • Russell 2000

    2,253.56
    -42.51 (-1.85%)
     
  • Crude Oil

    82.11
    -2.54 (-3.00%)
     
  • Gold

    1,799.00
    +5.60 (+0.31%)
     
  • Silver

    24.14
    +0.05 (+0.22%)
     
  • EUR/USD

    1.1604
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.5290
    -0.0900 (-5.56%)
     
  • GBP/USD

    1.3738
    -0.0025 (-0.18%)
     
  • USD/JPY

    113.8540
    -0.2750 (-0.24%)
     
  • BTC-USD

    59,349.77
    -2,674.61 (-4.31%)
     
  • CMC Crypto 200

    1,422.56
    -51.77 (-3.51%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • Nikkei 225

    29,098.24
    -7.77 (-0.03%)
     

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details on decision, analyst comment, background, share movement)

March 14 (Reuters) - The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.

Shares of Celgene were up 1.2 percent at $88.33 in early trading.

The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen's petition for an inter-partes review on the patents of the drug.

Drugmaker Bristol-Myers Squibb Co in January said it would buy Celgene for about $74 billion, to expand its pipeline of cancer drugs.

The court's decision helps in avoiding a potential issue that could unnerve investors ahead of the merger votes, RBC Capital Markets analysts wrote in a research note.

Revlimid, Celgene's cancer drug that brought in $2.55 billion revenue in the fourth quarter of 2018, could face loss of exclusivity from 2022 onwards in the United States.

Bristol-Myers has been defending the Celgene takeover as its "best path forward" in the face of opposition from two of its major shareholders. (Reporting by Manas Mishra in Bengaluru; Editing by James Emmanuel)